MedPath

Improving Knowledge of Medication in Ulcerative Colitis With an Iphone Application

Not Applicable
Completed
Conditions
Ulcerative Colitis
Registration Number
NCT02120391
Lead Sponsor
University of Wisconsin, Madison
Brief Summary

The purpose of this study is to assess an iPhone application to increase adherence to maintenance medications in subjects with ulcerative colitis.

Detailed Description

Inflammatory bowel disease is a chronic condition that requires maintenance medication to maintain clinical remission. During clinical remission patient can be free of symptoms for long periods of time. Inflammatory bowel disease patients have been shown to have adherence rates around 40-60%. Non-adherence in patients in clinical remission is high with rates around 60%. Non adherence in patients in clinical remission can have significant impact because it can lead to higher rates of clinical flares and increased health care cost.

This will be a single-blinded randomized controlled trial to evaluate if patients randomized to an iPphone application vs. control can increase the adherence of their maintenance medication. The trial will last three months and we hope to enroll 99 patients.

The primary outcome will be adherence measured by the medication possession ratio. The secondary objective will be to evaluate if a validated adherence questionnaire can predict adherence in patients with inflammatory bowel disease.

Having an intervention that can increase adherence can provide better care for patients. Also having a validated survey tool can accurately identify non-adherence in inflammatory bowel disease patient would be a valuable tool for patient care.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
39
Inclusion Criteria
  • At least 18 -65 years of age.
  • Diagnosed with ulcerative colitis established by history and biopsy confirmed by gastroenterology.
  • On a stable dose of mesalamine for at least two months prior to entering the study
  • Have an iPhone (personal iPhone)
  • Patient may receive steroid or mesalamine enemas during the study only on an as needed basis
Exclusion Criteria

• Are on more than one medication for their inflammatory bowel disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Medication adherence using iPhone App3 months
Secondary Outcome Measures
NameTimeMethod
Prediction of adherence using self-administered Brief Medication Questionnaire (BMQ)3 months

Trial Locations

Locations (1)

University of Wisconsin Hospital & Clinics

🇺🇸

Madison, Wisconsin, United States

University of Wisconsin Hospital & Clinics
🇺🇸Madison, Wisconsin, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.